Expansion of Umbilical Cord Blood Aldehyde Dehydrogenase Expressing Cells Generates Myeloid Progenitor Cells that Stimulate Limb Revascularization

Stem Cells Translational Medicine

Volumn 6, Issue 7, 2017, Pages 1607-1619

  Putman, David M ^a,b   Cooper, Tyler T ^a,b   Sherman, Stephen E ^a,b   Seneviratne, Ayesh K ^a,b   Hewitt, Mark ^b   Bell, Gillian I ^a   Hess, David A ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

Aldehyde dehydrogenase; Angiogenesis; Hematopoietic progenitor cell expansion; Peripheral artery disease; Transplantation; Umbilical cord blood

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANGIOPOIETIN 2; CD133 ANTIGEN; CD34 ANTIGEN; CHEMOKINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; EPIDERMAL GROWTH FACTOR; GELATINASE B; INTERLEUKIN 8; MESSENGER RNA; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LIGATION; ARTICLE; CAPILLARY DENSITY; CELL EXPANSION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPLANTATION; COCULTURE; COLONY FORMATION; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMORAL ARTERY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVASCULARIZATION; UMBILICAL CORD BLOOD CELL; VASCULAR ENDOTHELIAL CELL; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CONDITIONED MEDIUM; CYTOLOGY; DRUG EFFECT; GENETICS; ISCHEMIA; LIMB; METABOLISM; NONOBESE DIABETIC MOUSE; PHARMACOLOGY; PROCEDURES; SCID MOUSE; STEM CELL TRANSPLANTATION; TRANSPLANTATION; UMBILICAL CORD; VASCULARIZATION;

ALDEHYDE DEHYDROGENASE; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; EXTREMITIES; HUMANS; ISCHEMIA; MICE; MICE, INBRED NOD; MICE, SCID; MYELOID PROGENITOR CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELL TRANSPLANTATION; UMBILICAL CORD;

EID: 85021651490     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.1002/sctm.16-0472     Document Type: Article

References (53)

1. Lackland DT, Roccella EJ, Deutsch AF et al. Factors influencing the decline in stroke mortality: A statement from the American Heart Association/American Stroke Association. Stroke 2014;45:315–353.
2. Dotsenko O. Stem/Progenitor cells, atherosclerosis and cardiovascular regeneration. Open Cardiovasc Med J 2010;4:97–104.
3. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.
4. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: The scientific foundations of cardiac repair. J Clin Invest 2005;115:572–583.
5. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9:702–712.
6. Michler RE. Stem cell therapy for heart failure. Cardiol Rev 2014;22:105–116.
7. Gupta NK, Armstrong EJ, Parikh SA. The current state of stem cell therapy for peripheral artery disease. Curr Cardiol Rep 2014;16:447.
8. Botham CM, Bennett WL, Cooke JP. Clinical trials of adult stem cell therapy for peripheral artery disease. Methodist DeBakey Cardiovasc J 2013;9:201–205.
9. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701–705.
10. Murray CE, Soonpas MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;664–668.
11. Balsam LB, Wagers AJ, Christensen LJ et al. Hematopoietic stem cells adopt mature hematopoietic fates in ischemic myocardium. Nature 2004;428:668–673.
12. Rosenzweig A. Cardiac cell therapy–mixed results from mixed cells. N Engl J Med 2006;355:1274–1277.
13. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: Double-blind, randomised controlled trial. Lancet 2006;367:113–121.
14. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004;364:141–148.
15. Schachinger V, Erbs S, Elsässer A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210–1221.
16. Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002;360:427–435.
17. Higashi Y, Kimura M, Hara K et al. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb ischemia. Circulation 2004;109:1215–1218.
18. Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952–958.
19. Schatteman GC, Hanlon HD, Jiao C et al. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 2000;106:571–578.
20. Urbich C, Heeschen C, Aicher A et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003;108:2511–2516.
21. Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007;109:1801–1809.
22. Capoccia BJ, Robson DL, Levac KD et al. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 2009;113:5340–5351.
23. Hess DA, Craft TP, Wirthlin L et al. Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells 2008;26:611–620.
24. Wara AK, Croce K, Foo S et al. Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells: Implications for ischemic cardiovascular disease. Blood 2011;118:6461–6464.
25. Okuno Y, Nakamura-Ishizu A, Kishi K et al. Bone marrow-derived cells serve as proangiogenic macrophages but not endothelial cells in wound healing. Blood 2011;117:5264–5272.
26. Ohtani K, Vlachojannis GJ, Koyanagi M et al. Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells. Circ Res 2011;109:1219–1229.
27. Grunewald M, Avraham I, Dor Y et al. VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 2006;124:175–189.
28. Putman DM, Liu KY, Broughton HC et al. Umbilical cord blood-derived aldehyde dehydrogenase-expressing progenitor cells promote recovery from acute ischemic injury. Stem Cells 2012;30:2248–2260.
29. Perin EC, Silva G, Gahremanpour A et al. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv 2011;78:1060–1067.
30. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1–E7.
31. Tepper OM, Carr J, Allen RJ Jr. et al. Decreased circulating progenitor cell number and failed mechanisms of stromal cell-derived factor-1alpha mediated bone marrow mobilization impair diabetic tissue repair. Diabetes 2010;59:1974–1983.
32. Fadini GP, Sartore S, Albiero M et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006;26:2140–2146.
33. Jialal I, Devaraj S, Singh U et al. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: Implications for increased cardiovascular risk. Atherosclerosis 2010;211:297–302.
34. Perin EC, Murphy M, Cooke JP et al. Rationale and design for PACE: Patients with Intermittent claudication injected with ALDH bright cells. American Heart J 2014;168:667–673.
35. Bhatia M, Bonnet D, Kapp U et al. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term expansion. J.Exp Med 1997;186:619–624.
36. Chute JP, Muramoto GG, Whitesides J et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 2006;103:11707–11712.
37. Boitano AE, Wang J, Romeo R et al. Aryl hydrocarbon receptor antagonist promotes the expansion of human hematopoietic stem cells. Science 2011;329:1345–1348.
38. Csaszar E, Kirouac DC, Yu M et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. Cell Stem Cell 2012;10:218–229.
39. Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood 2011;117:6083–6090.
40. Seneviratne AK, Bell GI, Sherman SE et al. Expanded hematopoietic progenitor cells with high aldehyde dehydrogenase activity demonstrate islet regenerative functions. Stem Cells 2016;34:873–887.
41. Perin EC, Silva GV, Zheng Y et al. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am. Heart J 2012;163:415–21–421.e1.
42. Berezin AE, Kremzer AA. Circulating endothelial progenitor cells as markers for severity of ischemic chronic heart failure. J Card Fail 2014;6:438–447.
43. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res 2013;319:1271–1280.
44. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298–307.
45. Zhang F, Tang Z, Hou X et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009;106:6152–6157.
46. Holash J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994–1998.
47. Stanic B, Pandey D, Fulton DJ et al. Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2452–2460.
48. Kato M, Inazu T, Kawai Y et al. Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5. Biochem Biophys Res Commun 2003;301:1109–1115.
49. Dreux AC, Lamb DJ, Modjtahedi H et al. The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis. Atherosclerosis 2006;186:38–53.
50. Makki N, Thiel K, Miller F. The epidermal growth factor receptor and its ligands in cardiovascular disease. IJMS 2013;14:20597–20613.
51. Fiedler U, Scharpfenecker M, Koidl S et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150–4156.
52. Fiedler U, Augustin HG. Angiopoietins: A link between angiogenesis and inflammation. Trends Immunol 2006;27:552–558.
53. Crola Da Silva C, Lamerant-Fayel N et al. Selective human endothelial cell activation by chemokines as a guide to cell homing. Immunology 2009;126:394–404.